09-28-06 FW 1634 S



Attorney Docket No. 9237-23 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Ahuja et al.
Application No.: 10/089,595
Filed: September 23, 2002
For: Screening for Disease Susceptibility by Genotyping the CCR5 and CCR2 Genes

Confirmation No.: 2489
Group Art Unit: 1634
Examiner: Jehanne Souaya Sitton
Date: September 27, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §1.97(c)

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier.

In accordance with the requirements of 37 C.F.R. § 1.97(c)(2), a check for the $180.00 fee specified in 37 C.F.R. § 1.17(p) is enclosed. This amount is believed to be correct. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.56 and Section 609 of the MPEP.

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

Respectfully submitted,

Mary L. Miller
Registration No. 39303

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10
"Express Mail" mailing label number: EV 769236549 US
Date of Deposit: September 27, 2006
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan E. Freedman

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/089,595
		Filing Date	09/23/2002
		First Named Inventor	Sunil Ahuja
(use as many sheets as necessary)		Group Art Unit	1634
		Examiner Name	Jehanne Souaya Sitton
Sheet	**1 of 2**	Attorney Docket Number	9237-23

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			

U.S. PATENT APPLICATIONS				
Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY
		US-		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Anzala et al. CCR2-64I allele and genotype association with delayed AIDS progression in African women" *The Lancet* **351**:1632-1633 (1998)	
	2.	Biti et al. "HIV-1 infection in an individual homozygous for the *CCR5* deletion allele" *Nature Medicine* **3**(3):252-253 (1997)	
	3.	Dean et al. "Genetic Restriction of HIV-1 Infection and Progression to AIDS by Deletion Allele of the *CKR5* Structural Gene" *SCIENCE* **273**:1856-1862 (1996)	
	4.	Esposito et al. "Role of *CCR5* Chemokine Receptor Gene in Vertical Human Immunodeficiency Virus Type 1 Transmission and Disease Progression" *The Pediatric Infectious Disease Journal* **17**(9):847-849 (1998)	
	5.	Eugen-Olsen et al. "Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals" *AIDS* **11**:305-310 (1997)	
	6.	Eugen-Olsen et al. "Chemokine Receptor CCR2b 64I Polymorphism and its Relation to CD4 T-Cell Counts and Disease Progression in a Danish Cohort of HIV-Infected Individuals" *J. Acquir. Immune Def. Syndr. Hum. Retrovirol.* **18**:110-116 (1998)	
	7.	Garred et al. "Dual effect of CCR5 Δ32 gene deletion in HIV-1-infected patients" *The Lancet* **349**:1884 (1997)	
	8.	Garred et al. "Chemokine-receptor polymorphisms: clarity or confusion for HIV-1 prognosis?" *The Lancet* **351**:2-3 (1998)	
	9.	Hendel et al. "Distinctive Effects of *CCR5*, *CCR2* and *SDF1* Genetic Polymorphisms in AIDS Progression" *J. Acquir. Immune Def. Syndr. Hum. Retrovirol.* **19**:381-386 (1998)	
	10.	Huang et al. "The role of a mutant CCR5 allele in HIV-1 transmission and disease progression" *Nature Medicine* **2**(11):1240-1243 (1996)	
	11.	Husman et al. "Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection" *Annals of Internal Medicine* **127**(10):882-890 (1997)	
	12.	Ioannidis et al. "Genetic effects on HIV disease progression" *Nature Medicine* **4**(5):536 (1998)	
	13.	Just et al. "Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1" *The Journal of Pediatrics* **127**(4):544-549 (1995)	
	14.	Katzenstein et al. "HIV-Infected Individuals With the CCR Δ32/CCR5 Genotype Have Lower HIV RNA Levels and Higher CD4 Cell Counts in the Early Years of the Infection Than Do Patients With the Wild Type" *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* **16**:10-14 (1997)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/089,595
		Filing Date	09/23/2002
		First Named Inventor	Sunil Ahuja
		Group Art Unit	1634
(use as many sheets as necessary)		Examiner Name	Jehanne Souaya Sitton
Sheet	**2 of 2**	Attorney Docket Number	9237-23

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	15.	Kostrikis et al. "A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation" *Nature Medicine* **4**(3):350-353 (1998)	
	16.	Libert et al. "The *Δccr5* mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe" *Human Molecular Genetics* **7**(3):399-406 (1998)	
	17.	Lucotte, G. "Frequencies of the CC chemokine receptor 5 Δ32 allele in various populations of defined racial background" *Biomed & Pharmacother* **51**:469-473 (1997)	
	18.	Mandl et al. "Possible influence of the Mutant CCR5 Allele on Vertical Transmission of HIV-1" *Journal of Medical Virology* **55**:51-55 (1998)	
	19.	Mangano et al. "Distribution of *CCR-5 Δ32* allele in Argentinian children at risk of HIV-1 infection: its role in vertical transmission" *AIDS* **12**:109-123 (1998)	
	20.	Meyer et al. "Early protective effect of *CCR-5* Δ32 heterozygosity on HIV-1 disease progression: relationship with viral load" *AIDS* **11**:F73-F78 (1997)	
	21.	Michael et al. "The role of *CCR5* and *CCR2* polymorphisms in HIV-1 transmission and disease progression" *Nature Medicine* **3**(10):1160-1162 (1997)	
	22.	Michael et al. "The role of viral phenotype and *CCR-5* gene defects in HIV-1 transmission and disease progression" *Nature Medicine* **3**(3):338-340 (1997)	
	23.	Misrahi et al. "CCR5 Chemokine Receptor Variant in HIV-1 Mother-to-child Transmission and Disease Progression in Children" *JAMA* **279**(4):277-280 (1998)	
	24.	Morawetz et al. "Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCRS/Δccr5) genotype is neither essential nor sufficient for protection against disease progression" *Eur. J. Immunol.* **27**:3223-3227 (1997)	
	25.	O'Brien et al. "HIV-1 infection in a man homozygous for CCR5Δ32" *The Lancet* **349**:1219 (1997)	
	26.	Pal et al. "Inhibition of HIV-1 infection by the β-Chemokine MDC" *SCIENCE* **278**:695-698 (1997)	
	27.	Philpott et al. "CCR5 Genotype and Resistance to Vertical Transmission of HIV-1" *J. Acquir. Immune Defic. Syndr.* **21**:189-193 (1999)	
	28.	Quillent et al. "HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of *CCR5* gene" *The Lancet* **351**:14-18 (1998)	
	29.	Rizzardi et al. "CCR2 Polymorphism and HIV Disease" *Nature Medicine* **4**(3):252-253 (1998)	
	30.	Rousseau et al. "CCR5del32 in Perinatal HIV-1 Infection" *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* **16**:239-242 (1997)	
	31.	Shearer et al. "Cytokine Profiles in HIV Type 1 Disease and Protection" *AIDS Res. Hum. Retroviruses* **14**(Suppl 2):S149-S152 (1998)	
	32.	Shearer et al. "CCR5 HIV-1 Vertical Transmission" *J. Acquir. Immune Def. Syndr. Hum. Retroviol.* **17**:180-181 (1998)	
	33.	Smith et al. "Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression" *Science* **277**(5328):959-965 (1997)	
	34.	Tang et al. "Distribution of Chemokine Receptor *CCR2* and *CCR5* Genotypes and Their Relative Contribution to Human Immunodeficiency Virus Type 1 (HIV-1) Seroconversion, Early HIV-1 RNA Concentration in Plasma, and Later Disease Progression" *Journal of Virology* **76**(2):662-672 (2002)	
	35.	Theodorou et al. "HIV-1 infection in an individual homozygous for CCR5Δ32" *The Lancet* **349**:1219-1220 (1997)	
	36.	Van Rij et al. "Role of CCR2 Genotype in the Clinical Course of Syncytium-Inducing (SI) or Non-SI Human Immunodeficiency Virus Type 1 Infection and in the Time to Conversion to SI Virus Variants" *JID* **178**:1806-1811 (1998)	
	37.	Winkler et al. "Genetic Restriction of AIDS Pathogenesis by an SDF-1 Chemokine Gene Variant" *SCIENCE* **279**:389-393 (1998)	
	38.	Zimmerman et al. "Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical Phenotypes, Defined Racial Background, and Quantified Risk" *Mol. Med.* **3**(1):23-36 (1997)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.